Substances from the medicinal mushroom Daedalea gibbosa inhibit kinase activity of native and T315I mutated Bcr-Abl

International Journal of Oncology

Volumn 32, Issue 6, 2008, Pages 1197-1204

  Yassin, Majed ^a,b   Wasser, Solomon P ^b   Mahajna, Jamal ^a  

^a MIGAL GALILEE TECHNOLOGY CENTER   (Israel)

^b UNIVERSITY OF HAIFA   (Israel)

Author keywords

Antitumor activity; Apoptosis; Bcr Abl; Chronic myelogenous leukemia; Daedalea gibbosa; Differentiation; Kinase; Medicinal mushrooms

Indexed keywords

BCR ABL PROTEIN; DAEDALEA GIBBOSA EXTRACT; IMATINIB; NATURAL PRODUCT; PHOSPHOTRANSFERASE; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; ABELSON KINASE; BCR ABL TYROSINE KINASE; BCR-ABL TYROSINE KINASE; FUNGAL PROTEIN; PIPERAZINE DERIVATIVE; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CANCER CELL CULTURE; CELL STRAIN K 562; CHRONIC MYELOID LEUKEMIA; COLONY FORMATION; CONTROLLED STUDY; DAEDALEA GIBBOSA; DRUG PURIFICATION; ENZYME INHIBITION; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; INHIBITION KINETICS; MITOSIS INHIBITION; MOUSE; MUSHROOM; MYCELIUM; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; AGARICALES; ANIMAL; CELL CULTURE; CELL DIFFERENTIATION; CELL PROLIFERATION; CHEMISTRY; CLONOGENIC ASSAY; DRUG ANTAGONISM; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; ISOLATION AND PURIFICATION; METABOLISM; MUTATION; PATHOLOGY; PHOSPHORYLATION; WESTERN BLOTTING;

AGARICALES; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; COLONY-FORMING UNITS ASSAY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FUNGAL PROTEINS; HUMANS; K562 CELLS; MICE; MUTATION; PHOSPHORYLATION; PIPERAZINES; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-ABL; PYRIMIDINES;

EID: 48149085407     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo_32_6_1197     Document Type: Article

References (36)

1. Mizuno T: The extraction and development of antitumor-active polysaccharides from medicinal mushrooms in Japan (review). Int J Med Mushr 1: 9-29, 1999.
2. Wasser SP: Medicinal mushrooms as a source of antitumor and immunomodulating polysaccharides. Appl Microbiol Biotechnol 60: 258-274, 2002.
3. Chang ST: A 40-year journey through bioconversion of lignocellulosic wastes to mushrooms and dietary supplements. Int J Med Mushr 3: 299-310, 2001.
4. Yassin M, Mahajna J and Wasser SP: Submerged cultured mycelium extracts of higher basidiomycetes mushrooms selectively inhibit proliferation and induce differentiation of K562 human chronic myelogenous leukemia cells. Int J Med Mushr 5: 261-276, 2003.
5. Zaidman BZ, Yassin M, Mahajna J and Wasser SP: Medicinal mushroom modulators of molecular targets as cancer therapeutics. Appl Microbiol Biotechnol 67: 453-468, 2005.
6. Petrova RD, Wasser SP, Mahajna J, Denchev CM and Nevo E: Medicinal Mushrooms: A new source for breast cancer therapeutics. Int J Med Mushr 7: 445-446, 2005.
7. Zaidman B, Wasser SP, Nevo E and Mahajna J: Androgen receptor-dependent and independent mechanisms mediates Ganoderma Lucidium activity on LNCaP prostate cancer cells. Int J Oncol 4: 959-967, 2007,
8. Petrova RD, Mahajna J, Reznick AZ, Wasser SP, Denchev CM and Nevo E: Fungal substances as modulators of NF-kB activation pathway. Mol Biol Rep 34: 145-154, 2007.
9. Faderl S, Talpaz M, Estrov Z and Kantarjian HM: Chronic myelogenous leukemia: biology and therapy. Ann Intern Med 131: 207-219, 1999.
10. Li S, Ilaria RL Jr, Million RP, Daley GQ and Van Etten RA: The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J Exp Med 189: 1399-1412, 1999.
11. Sawyers CL, Hochhaus A, Feldman E, et al: Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 99: 3530-3539, 2002.
12. Taipaz M, Silver RT, Druker BJ, et al: Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 99: 1928-1937, 2002.
13. Ottmann OG, Wassmann B and Hoelzer D: Imatinib for relapsed BCR/ABL positive leukemias. Ann Hematol 81: S36-S37, 2002.
14. Gambacorti-Passerini CB, Gunby RH, Piazza R, Galietta A, Rostagno R and Scapozza L: Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol 4: 75-85, 2003.
15. Azam M, Latek RR and Daley GQ: Mechanisms of autoinhibition and STI-571/ imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 112: 831-843, 2003.
16. Shah NP, Tran C, Lee FY, Chen P, Norris D and Sawyers CL: Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305: 399-401, 2004.
17. Hochhaus A and La Rosee P: Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia 18: 1321-1331, 2004.
18. Hofmann WK, Komor M, Wassmann B, et al: Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia. Blood 102: 659-661, 2003.
19. O'Hare T, Walters DK, Stoffregen EP, et al: In vitro activity of Bcr-Ab1 inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Ab1 kinase domain mutants. Cancer Res 65: 4500-4505, 2005.
20. Cheetham GM, Charlton PA, Golec JM and Pollard JR: Structural basis for potent inhibition of the Aurora kinases. Cancer Lett 251: 329-9, 2007.
21. Maekawa T, Ashihara E and Kimura S: The Bcr-Ab1 tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias. Int J Clin Oncol 12: 327-340, 2007.
22. Wasser SP, Lewinsohn D and Duckman I: Culture Collection of Higher Basidiomycetes of the Haifa University. Peledfus Press, Haifa, 2002.
23. Acs P, Beheshti M, Szallasi Z, Li L, Yuspa SH and Blumberg PM: Effect of a tyrosine 155 to phenylalanine mutation of protein kinase cdelta on the proliferative and tumorigenic properties of NIH 3T3 fibroblasts. Carcinogenesis 21: 887-891, 2000.
24. Roehm NW, Rodgers GH, Hatfield SM and Glasebrook AL: An improved understanding of the pathogenesis of CML: A prototype of early neoplasia. Leukemia 11: 1404-1428, 1991.
25. Ray S, Bullock G, Nuñez G, et al: Enforced expression of Bc1-xS induces differentiation and sensitizes CML-blast crisis K562 cells to Ara-C mediated differentiation and apoptosis. Cell Growth Differ 7: 1617-1623, 1996.
26. Lozzio CB and Lozzio BB: Properties and usefulness of the original K-562 human myelogenous leukemia cell line. Blood 45: 321-334, 1975.
27. Leary JF, Farley BA, Giuliano R, Kosciolek BA, La Bella S and Rowley PT: Induction of megakaryocytic characteristics in human leukemic cell line k562: polyploidy, inducers, and secretion of mitogenic activity. J Biol Regul Homeost Agents 1: 73-80, 1987.
28. McGowan AJ, Ruiz-Ruiz MC, Gorman AM, Lopez-Rivas A and Cotter TG: Reactive oxygen intermediate(s) (ROI): Common mediator(s) of poly(ADP-ribose)polymerase (PARP) cleavage and apoptosis. FEBS Lett 392: 299-303, 1996.
29. Weisberg E, Manley PW, Breitenstein W, et al: Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Ab1. Cancer Cell 7: 129-141, 2005.
30. Wolff NC, Veach DR, Tong WP, Bornmann WG, Clarkson B and Ilaria RL Jr: PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia. Blood 105: 3995-4003, 2005.
31. Villeval JL, Pelicci PG, Tabilio A, et al: Erythroid properties of K562 cells. Effect of hemin, butyrate and TPA induction. Exp Cell Res 146: 428-435, 1983.
32. Nagel RL, Fabry ME, Pagnier J, et al: Hematologically and genetically distinct forms of sickle cell anemia in Africa, The Senegal type and the Benin type. N Engl J Med 312: 880-884, 1985.
33. Labie D, Pagnier J, Lapoumeroulie C, et al: Common haplotype dependency of high G gamma-globin gene expression and high Hb F levels in beta-thalassemia and sickle cell anemia patients. Proc Natl Acad Sci USA 82: 2111-2114, 1985.
34. Fujii T, Maeda H, Suzuki F and Ishida N: Isolation and characterization of a new antitumor polysaccharide, KS-2, extracted from culture mycelia of Lentinus edodes. J Antibiot 31: 1079-1090, 1978.
35. Ying J, Mao X, Ma Q, Zong Z and Wen H: Icons of Medicinal Fungi from China. Yuehan X (ed). Science Press, Beijing, 1987. Translated.
36. Yoshikawa K, Kouso K, Takahashi J, et al: Cytotoxic constituents of the fruit body of Daedalea dickisii. J Nat Prod 68: 911-914, 2005.